Aetna Deems XDx AlloMap Test 'Medically Necessary' for Monitoring Heart Transplant Patients

The decision means that "Aetna has decided to pay for AlloMap as a matter of policy," an XDx spokesperson said. Prior to the policy decision, "Aetna would require medical justification for each test to consider whether or not to pay" for it.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.